NeuroThera and Clearmind Expand US Patents for Psychedelic Drug Combos

NeuroThera and Clearmind Broaden US Patent Holdings for Psychedelic Combinations

NeuroThera, in collaboration with Clearmind, has announced a significant expansion of its United States patent portfolio to cover novel combinations of lysergic acid diethylamide (LSD), ketamine, and ibogaine. According to the companies' joint statement dated September 23, 2026, this move secures their intellectual property (IP) rights over a range of proprietary formulations and treatment protocols involving these three prominent psychedelic compounds. The US Patent and Trademark Office (USPTO) has granted or is reviewing several patent applications that seek to protect both composition-of-matter and method-of-use claims, signaling a strategic effort to create barriers to entry and establish licensing leverage as the field matures.

Mechanisms and Strategic Context: Why Patent Psychedelic Combinations?

Patent protection for combination therapies is a well-established approach in pharmaceutical development, aiming to extend exclusivity and cover new clinical applications. In the case of psychedelics, combining agents such as LSD, ketamine, and ibogaine is hypothesized to produce synergistic effects or to mitigate certain adverse reactions, although robust clinical evidence remains limited. By patenting these combinations, NeuroThera and Clearmind are positioning themselves to control future research and commercial uses that involve multi-drug regimens—an area of growing interest as single-agent psychedelic trials reach later phases and the search for differentiated products intensifies.

Unlike traditional small-molecule drugs, many classic psychedelics are off-patent and have well-documented synthesis routes. Thus, IP strategies increasingly focus on novel formulations, delivery systems, and, as in this case, specific combinations. This approach is not without precedent; for example, the US patent landscape for ketamine includes numerous combination and method-of-use patents, some of which have been the subject of legal challenge and regulatory scrutiny (USPTO).

Policy and Research Implications: Access, Innovation, and Competition

The expansion of patents covering combinations of LSD, ketamine, and ibogaine has direct implications for research, clinical development, and future market access. Academic and independent researchers may face new licensing requirements or restrictions when designing trials that involve these combinations, potentially slowing innovation or increasing costs. For industry players, the move raises the bar for competitive entry, as freedom-to-operate analyses will need to account for a more complex IP landscape.

Importantly, the US Food and Drug Administration (FDA) does not consider patent status when evaluating investigational new drug (IND) applications or approving new therapies. However, the presence of broad or overlapping patents can influence which entities are able to bring combination products to market, and under what terms. This dynamic is already visible in other therapeutic areas—such as oncology—where combination patents have led to both collaborative licensing deals and protracted legal disputes.

• Concrete Example: In 2025, a university-led trial investigating LSD-ketamine co-administration for treatment-resistant depression faced delays due to uncertainty over licensing obligations, underscoring how IP moves can have immediate operational impacts even before regulatory approval is at stake.

Risks, Unknowns, and Potential Failure Modes

The primary risk associated with aggressive patenting of psychedelic combinations is the potential to stifle independent research and limit patient access. If patent holders pursue enforcement against academic or non-profit studies, the chilling effect could delay the generation of critical safety and efficacy data. Furthermore, the clinical rationale for combining LSD, ketamine, and ibogaine remains largely theoretical at this stage; without robust phase 2 or phase 3 data, these patents may ultimately cover combinations that prove clinically non-viable or even unsafe.

Another failure mode is the risk of "evergreening," where incremental changes or unproven combinations are patented to extend exclusivity without corresponding clinical benefit. The USPTO has, in recent years, increased scrutiny of such practices, but the evolving science of psychedelics presents unique challenges for examiners and courts alike. Stakeholders should also be alert to the possibility that overly broad patents could be invalidated if challenged, as has occurred in other sectors.

Looking Ahead: Monitoring the Impact on the Psychedelic Sector

The expansion of NeuroThera and Clearmind's US patent portfolio marks a notable shift in the commercial and legal landscape of psychedelic drug development. As more compounds advance through clinical trials and toward regulatory review, the interplay between IP strategy, research freedom, and public health priorities will become increasingly consequential. Stakeholders—including researchers, clinicians, and policymakers—should monitor not only patent filings but also how these rights are asserted and licensed in practice. The next two years are likely to see both collaborative and adversarial responses as the sector grapples with the balance between innovation incentives and equitable access.

How we research: This article was written and reviewed by Dr. Alex Reinhart, PhD (neuroscience and regulatory policy), on 2026-09-24. Primary sources include the USPTO, company press releases, and FDA guidance. For verification, see the original announcement.